HomeTag Stuart Therapeutics

Stuart Therapeutics, Inc. Announces Key Addition to its Executive Team

Company adds Lukas Scheibler as Chief Science and Technology Officer STUART, Fla., July 25, 2024 /PRNewswire/ — Stuart Therapeutics, a clinical-stage ophthalmic biopharmaceutical company focused on developing therapies for the treatment of anterior segment, refractive and posterior segment eye disorders, today announced the addition of Lukas Scheibler, PhD as its Chief Science and Technology Officer. “The advancement of our pipeline...

Stuart Therapeutics, Inc. Announces Upcoming Presentations at ARVO 2024

Presentations at the OIS- and Ora-sponsored Dry Horizons meeting on May 3rd, at OIS Retina on May 4th, and a poster at ARVO STUART, Fla., April 19, 2024 /PRNewswire/ — Stuart Therapeutics, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing therapies for the treatment of anterior segment, refractive and posterior segment eye disorders, today announced that the company will...

Stuart Therapeutics Announces Chief Medical and Chief Financial Officer Appointments

STUART, Fla., Feb. 1, 2024 /PRNewswire/ — Stuart Therapeutics, Inc. (“Stuart“), a clinical-stage biopharmaceutical company with candidate therapeutics in various phases of clinical development, today announced that it has appointed Jodi Luchs, MD to the position of Chief Medical Officer, and Don Stires to the position of Chief Financial Officer. With the appointment of Dr. Luchs, Robert Baratta, MD has stepped...

Stuart Therapeutics, Inc. announces licensing agreement with Aju Pharm Co. Ltd.

STUART, Fla., Jan. 3, 2023 /PRNewswire/ — Stuart Therapeutics, Inc., (hereinafter Stuart) announces that it has entered into a license agreement with AJU Pharm Co. Ltd. (hereinafter AJU), for Stuart’s clinical stage drug candidate ST-100. Under this agreement, AJU has the exclusive right to develop and commercialize ST-100 for South Korean and certain Southeast Asian markets in exchange for certain...

Stuart Therapeutics, Inc. Announces Successful Phase 2 Clinical Trial Results of its Novel Dry Eye Candidate ST-100

Stuart Therapeutics, Inc. Announces Successful Phase 2 Clinical Trial Results of its Novel Dry Eye Candidate ST-100   – Achieved FDA Pre-Approved Single Primary Endpoint After 28 Days of Administration – Improvement in Total Ocular Discomfort after 14 Days   STUART, Fla., Jan. 3, 2022 /PRNewswire/ — Stuart Therapeutics, Inc. (STUART), a clinical stage, innovative ophthalmic...

Stuart Therapeutics, Inc. Announces Completion of Patient Enrollment in Phase 2 Clinical Trial for Dry Eye Disease

Stuart Therapeutics, Inc. Announces Completion of Patient Enrollment in Phase 2 Clinical Trial for Dry Eye Disease STUART, Fla., Sept. 8, 2021 /PRNewswire/ — Stuart Therapeutics, Inc. (“Stuart“), a clinical stage biopharmaceutical company conducting research and development of unique peptide therapeutics for ophthalmic diseases, today announced that it has completed patient enrollment in its Phase 2...

Stuart Therapeutics Completes its $11M Series A Round, led by InFocus Capital Partners, WARF and MiMo Capital

Stuart Therapeutics Completes its $11M Series A Round, led by InFocus Capital Partners, WARF and MiMo Capital Stuart Therapeutics, Inc. (“Stuart”), a clinical stage biopharmaceutical company conducting research and development of unique peptide therapeutics for ophthalmic diseases, today announced the completion of an $11 million Series A round of capital investment. The round was led...